Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicinesDesignation granted for warm autoimmune hemolytic anemia and IgG4-related…Read More
You might also be interested in reading BigBear.ai tanks on earnings, but analysts remain high on long-term opportunity.